title: Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
abstract: BACKGROUND
  Several chemotherapy agents, including gemcitabine and paclitaxel, have been reported to cause interstitial pneumonitis. The incidence of pulmonary toxicity from the combination of gemcitabine and paclitaxel is reported to be approximately 5%. In this report, pulmonary function test (PFT) results were analyzed from two similar randomized phase 2 trials that tested platinum and nonplatinum regimens preoperatively in patients with stage I or II non-small cell lung cancer (NSCLC).
  
  
  METHODS
  The regimens included gemcitabine plus carboplatin, paclitaxel, or cisplatin. PFT and dyspnea scores were obtained at baseline and postchemotherapy, and were compared to one of several secondary end points, including ability to undergo surgical resection.
  
  
  RESULTS
  Baseline PFT scores varied with smoking status. Mean levels of diffusing capacity of the lung for carbon monoxide (Dlco) adjusted for hemoglobin declined 8% from pre- to postinduction (Wilcoxon signed rank test, p < 0.0001). Changes in FVC, FEV(1), and total lung capacity were not statistically significant after chemotherapy. Although 27% of patients in the study had some reduction in PFT results, only 2 of the 85 eligible patients did not undergo surgery due to PFT reduction following chemotherapy. One patient in the study experienced a clinically significant respiratory toxicity (grade 3 dyspnea). Pulmonary toxicity was only statistically associated with male gender.
  
  
  CONCLUSIONS
  In the preoperative setting, gemcitabine-based chemotherapy was well tolerated. The most commonly affected PFT parameter postchemotherapy was the Dlco. Although 15% of patients had a significant reduction in the Dlco postchemotherapy, it did not correlate with clinical symptoms or affect the ability to undergo surgical resection.
authors.affiliation: Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: mprivera@med.unc.edu.
authors.forename: M Patricia
authors.initials: MP
authors.lastname: Rivera
authors.affiliation: Yale Comprehensive Cancer Center, Yale University, New Haven, CT.
authors.forename: Frank C
authors.initials: FC
authors.lastname: Detterbeck
authors.affiliation: Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
authors.affiliation: Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Dominic T
authors.initials: DT
authors.lastname: Moore
authors.affiliation: University of Maryland Greenebaum Cancer Center, Baltimore, MD.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Edelman
authors.affiliation: University of California San Francisco, San Francisco, CA.
authors.forename: Thierry M
authors.initials: TM
authors.lastname: Jahan
authors.affiliation: Michiana Hematology/Oncology, South Bend, IN.
authors.forename: Rafat H
authors.initials: RH
authors.lastname: Ansari
authors.affiliation: University of Pittsburgh Physicians, Pittsburgh, PA.
authors.forename: James D
authors.initials: JD
authors.lastname: Luketich
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Guangbin
authors.initials: G
authors.lastname: Peng
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Matthew
authors.initials: M
authors.lastname: Monberg
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Coleman K
authors.initials: CK
authors.lastname: Obasaju
authors.affiliation: North Shore-Long Island Jewish Health System, Lake Success, NY.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Gralla
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D016001:Confidence Intervals; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011013:Pneumonectomy / Q000379:methods / Q000401:mortality; D011300:Preoperative Care; D011336:Probability; D012129:Respiratory Function Tests; D018570:Risk Assessment; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine